Compound Evidence File
#EC-2026-0264
Retatrutide Raw
Filed under Raw Materials. The bureau holds 105 laboratory returns for this compound from 37 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
37 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 10.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 10.0 | 10.0 | 28 Nov 2025 | 28 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 9.9 | 10.0 | 1 Mar 2026 | 3 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 9.9 | 10.0 | 11 Jan 2026 | 11 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 10.0 | 10.0 | 22 Nov 2025 | 18 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 10.0 | 10.0 | 13 Mar 2026 | 9 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 10.0 | 10.0 | 3 Mar 2026 | 4 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 10.0 | 10.0 | 10 Dec 2025 | 16 Apr 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Feb 2026 | 4 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 24 Dec 2025 | 15 Apr 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 9.9 | 9.9 | 10.0 | 15 Apr 2026 | 26 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 15 Jun 2026 | 23 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 13 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 9.9 | 16 Apr 2026 | 26 Jun 2026 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 9.6 | 9.6 | 9.6 | 3 Jun 2025 | 3 Jun 2025 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 9.3 | 9.3 | 9.3 | 11 Jun 2025 | 11 Jun 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 9.1 | 7.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 9.1 | 7.7 | 10.0 | 21 May 2026 | 21 May 2026 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 8.8 | 8.8 | 8.8 | 17 Dec 2024 | 17 Dec 2024 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.4 | 7.2 | 10.0 | 23 May 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 8.4 | 8.0 | 8.8 | 25 May 2026 | 25 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 8.0 | 6.9 | 9.3 | 24 May 2026 | 24 May 2026 |
| Eros PeptidesCASE #VI-2026-0918 | X | 1 | 7.5 | 7.5 | 7.5 | 20 Jun 2025 | 20 Jun 2025 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 1 | 7.2 | 7.2 | 7.2 | 3 Jul 2025 | 3 Jul 2025 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 3 | 7.1 | 4.1 | 10.0 | 8 Jul 2025 | 21 May 2026 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 2 | 7.1 | 6.9 | 7.2 | 14 Jan 2025 | 25 May 2026 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 1 | 6.5 | 6.5 | 6.5 | 11 Jun 2025 | 11 Jun 2025 |
| OmegAminoCASE #VI-2026-0014 | X | 1 | 6.4 | 6.4 | 6.4 | 6 May 2025 | 6 May 2025 |
| NextechLabsCASE #VI-2026-0285 | X | 1 | 6.4 | 6.4 | 6.4 | 3 Jun 2025 | 3 Jun 2025 |
| HXNetCASE #VI-2026-0061 | X | 8 | 6.3 | 5.1 | 10.0 | 20 Jun 2025 | 26 Jan 2026 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 5.8 | 5.8 | 5.8 | 28 Mar 2025 | 28 Mar 2025 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 2 | 5.7 | 4.1 | 7.2 | 7 May 2025 | 20 May 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 3 | 5.4 | 4.4 | 6.9 | 21 May 2025 | 17 May 2026 |
| Amino AsylumCASE #VI-2026-0828 | X | 1 | 4.5 | 4.5 | 4.5 | 13 Jun 2025 | 13 Jun 2025 |
| Shenzhen Jiechuang TradingCASE #VI-2026-0292 | X | 1 | 3.4 | 3.4 | 3.4 | 7 May 2025 | 7 May 2025 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 2.0 | 2.0 | 2.0 | 27 Feb 2025 | 27 Feb 2025 |
Open any subject to view the batch-level evidence for Retatrutide Raw alone.